MARKET

OSUR

OSUR

Orasure Tech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.510
-1.060
-19.03%
After Hours: 4.780 +0.27 +5.99% 16:09 05/24 EDT
OPEN
5.56
PREV CLOSE
5.57
HIGH
5.58
LOW
4.200
VOLUME
2.59M
TURNOVER
0
52 WEEK HIGH
13.57
52 WEEK LOW
4.200
MARKET CAP
326.77M
P/E (TTM)
-6.9567
1D
5D
1M
3M
1Y
5Y
OraSure Technologies gets new CEO
OraSure Technologies (NASDAQ:OSUR) announces that Carrie Eglinton Manner has been appointed President and CEO, effective June 4, 2022.  Ms. Eglinton Manner will also join the Board of Directors. She succeeds Dr. Nancy Gagliano, who was appointed
Seekingalpha · 1d ago
OraSure Technologies Names Carrie Eglinton Manner President and Chief Executive Officer
MT Newswires · 1d ago
BRIEF-Inteliswab COVID-19 Rapid Test Validated To Detect The Omicron Ba.2, Ba.2.12.1, Ba.3 And Ba.5 Subvariants
reuters.com · 05/17 11:19
InteliSwab® COVID-19 Rapid Test Validated to Detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 Subvariants
InteliSwab test With less than one minute of “hands-on time,” the InteliSwab test is as simple as “Swab, Swirl, and See.” BETHLEHEM, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home ...
GlobeNewswire · 05/17 11:05
--Citigroup Lowers OraSure Technologies Price Target to $10 From $12, Buy Rating Kept
MT Newswires · 05/11 09:54
OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates
OraSure (OSUR) delivered earnings and revenue surprises of -100% and 4.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 22:55
OraSure Technologies Q1 EPS $(0.28) Down From $0.05 YoY, Sales $67.71M Up From $58.58M YoY
OraSure Technologies (NASDAQ:OSUR) reported quarterly losses of $(0.28) per share. This is a 660 percent decrease over earnings of $0.05 per share from the same period last year. The company reported $67.71 million in
Benzinga · 05/10 20:24
OraSure Technologies GAAP EPS of -$0.28, revenue of $67.71M
OraSure Technologies press release (NASDAQ:OSUR): Q1 GAAP EPS of -$0.28. Revenue of $67.71M (+15.6% Y/Y). Shares -1%.
Seekingalpha · 05/10 20:19
More
No Data
Learn about the latest financial forecast of OSUR. Analyze the recent business situations of Orasure Tech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

16.67%Strong Buy
16.67%Buy
66.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average OSUR stock price target is 8.88 with a high estimate of 10.00 and a low estimate of 7.00.
High10.00
Average8.88
Low7.00
Current 4.510
EPS
Actual
Estimate
-0.21-0.15-0.08-0.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 289
Institutional Holdings: 79.46M
% Owned: 109.67%
Shares Outstanding: 72.46M
TypeInstitutionsShares
Increased
62
3.24M
New
19
3.53M
Decreased
61
1.99M
Sold Out
20
1.73M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.84%
Healthcare Equipment & Supplies
-0.34%
Key Executives
Non-Executive Chairman/Independent Director
Michael Celano
Chief Executive Officer/Director
Nancy Gagliano
Chief Financial Officer/Senior Vice President/Director of Investor Relations
Scott Gleason
Corporate Executive
Lisa Nibauer
Corporate Executive
Kathleen Weber
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Agnieszka Gallagher
Senior Vice President/Chief Accounting Officer/Controller/Secretary
Michele Miller
Independent Director
Mara Aspinall
Independent Director
James Datin
Independent Director
Eamonn Hobbs
Independent Director
Ronny Lancaster
Independent Director
Lelio Marmora
Independent Director
David Shulkin
Independent Director
Anne Whitaker
No Data
No Data
About OSUR
OraSure Technologies, Inc. (OraSure) is a medical device company that develops, manufactures, and markets medical devices and diagnostic products. The Company's products include molecular sampling kits for the genome and microbiome services and analytics, rapid diagnostics for infectious disease, and tests for substance abuse. OraSure’s segments include Diagnostics segment and Molecular Collection Systems segment. The Diagnostics business primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices. The Molecular Solutions business consists of the manufacture and sale of kits that are used to collect, stabilize, transport and store biological samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbiome and animal genetics markets.

Webull offers kinds of OraSure Technologies, Inc. stock information, including NASDAQ:OSUR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OSUR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OSUR stock methods without spending real money on the virtual paper trading platform.